FMR1 and fragile X syndrome: More commonly prescribed for its antibiotic properties, the benefits of minocycline in FXS are thought to be enacted through the inhibition of matrix metalloproteinase-9 (MMP9) [138], a locally translated protein, regulated by FMRP and overexpressed in FXS [137, 139].